BACKGROUND: There are limited data assessing relationships between biomarkers of inflammation and lung function after hospitalization for asthma exacerbations in children. OBJECTIVE: To assess the associations in asthmatic children among changes in lung function, fraction of exhaled nitric oxide (FENO), and cysteinyl leukotrienes (CysLTs) in exhaled breath condensate (EBC) after hospitalization for acute asthma. METHODS: Spirometry and FENO were measured and EBC collected for CysLT measurement from 40 children during and 1, 2, and 4 weeks after hospitalization for an asthma exacerbation and during a single-study visit for 40 healthy children. RESULTS: Enrollment FENO and EBC CysLT concentrations were higher in the children with asthma than in healthy individuals (mean FENO, 31.6 vs 7 ppb; P < .0001; mean EBC CysLT, 7.9 vs 4.9 ppb; P = .03). Among children with asthma, improvement in lung function reached a plateau within 2 weeks after hospital discharge. The EBC CysLT concentrations were not associated with changes in lung function, use of albuterol, or use of inhaled corticosteroids (ICSs). Among asthmatic children enrollment FENO was not associated with changes in lung function during follow-up. However, among children who had an elevated enrollment FENO (≥25 ppb), patients who did not use ICSs after hospital discharge had lower end-of-study lung function than those who used ICSs. At 2 and 4 weeks after hospital discharge, FENO was higher among patients who reported albuterol use more than twice weekly and among patients who reported no ICS use. CONCLUSION: FENO measured at hospital discharge among children hospitalized with acute asthma may be useful in identifying patients who will respond to ICS therapy.
BACKGROUND: There are limited data assessing relationships between biomarkers of inflammation and lung function after hospitalization for asthma exacerbations in children. OBJECTIVE: To assess the associations in asthmatic children among changes in lung function, fraction of exhaled nitric oxide (FENO), and cysteinyl leukotrienes (CysLTs) in exhaled breath condensate (EBC) after hospitalization for acute asthma. METHODS: Spirometry and FENO were measured and EBC collected for CysLT measurement from 40 children during and 1, 2, and 4 weeks after hospitalization for an asthma exacerbation and during a single-study visit for 40 healthy children. RESULTS: Enrollment FENO and EBC CysLT concentrations were higher in the children with asthma than in healthy individuals (mean FENO, 31.6 vs 7 ppb; P < .0001; mean EBC CysLT, 7.9 vs 4.9 ppb; P = .03). Among children with asthma, improvement in lung function reached a plateau within 2 weeks after hospital discharge. The EBC CysLT concentrations were not associated with changes in lung function, use of albuterol, or use of inhaled corticosteroids (ICSs). Among asthmatic children enrollment FENO was not associated with changes in lung function during follow-up. However, among children who had an elevated enrollment FENO (≥25 ppb), patients who did not use ICSs after hospital discharge had lower end-of-study lung function than those who used ICSs. At 2 and 4 weeks after hospital discharge, FENO was higher among patients who reported albuterol use more than twice weekly and among patients who reported no ICS use. CONCLUSION:FENO measured at hospital discharge among children hospitalized with acute asthma may be useful in identifying patients who will respond to ICS therapy.
Authors: Zsuzsanna Csoma; Sergei A Kharitonov; Beatrix Balint; Andrew Bush; Nicola M Wilson; Peter J Barnes Journal: Am J Respir Crit Care Med Date: 2002-09-05 Impact factor: 21.405
Authors: J M Sippel; W E Holden; S A Tilles; M O'Hollaren; J Cook; N Thukkani; J Priest; B Nelson; M L Osborne Journal: J Allergy Clin Immunol Date: 2000-10 Impact factor: 10.793
Authors: Alessandra Sandrini; Ivone M Ferreira; Carlos Gutierrez; Jose R Jardim; Noe Zamel; Kenneth R Chapman Journal: Chest Date: 2003-10 Impact factor: 9.410
Authors: E Baraldi; S Carraro; R Alinovi; A Pesci; L Ghiro; A Bodini; G Piacentini; F Zacchello; S Zanconato Journal: Thorax Date: 2003-06 Impact factor: 9.139
Authors: Robert C Strunk; Stanley J Szefler; Brenda R Phillips; Robert S Zeiger; Vernon M Chinchilli; Gary Larsen; Kevin Hodgdon; Wayne Morgan; Christine A Sorkness; Robert F Lemanske Journal: J Allergy Clin Immunol Date: 2003-11 Impact factor: 10.793
Authors: Dillys van Vliet; Ariel Alonso; Ger Rijkers; Jan Heynens; Philippe Rosias; Jean Muris; Quirijn Jöbsis; Edward Dompeling Journal: PLoS One Date: 2015-03-23 Impact factor: 3.240